Invega Sustenna (paliperidone palmitate)
Invega Sustenna (paliperidone palmitate, monthly injection)
Brand name: Invega® Sustenna®
Active ingredient: Paliperidone palmitate
Type: Atypical antipsychotic
Available from: Janssen Inc.
Form: Long‑acting injection
Generic: No
Listed on Ontario formulary: Yes (with suggested criteria*)
OHIP+ coverage: Yes (with suggested criteria*)
*Suggested for individuals with non‑adherence AND inadequate control/side effects on:
≥2 oral antipsychotics or
≥1 typical depot antipsychotic
What is Invega Sustenna used for?
Monthly long‑acting injection for schizophrenia and related psychotic illnesses in adults.
How should I take Invega Sustenna?
Administered by a healthcare provider.
Available in 50 mg, 75 mg, 100 mg, and 150 mg prefilled syringes.
Starter dosing:
- 1st injection →
- 2nd injection after 1 week →
- Then monthly
Your doctor adjusts the dosage based on your response.
Common side effects
- Headache
- Insomnia
- Constipation
- Nausea/vomiting
- Injection‑site pain
- Weight gain
- Restlessness (akathisia)
- Dizziness
- Abnormal movements (EPS)
Rare but serious side effects
Same as oral Invega:
- Agranulocytosis
- Stroke
- Severe allergic reaction
- DKA
- NMS
Warnings/Precautions
Not approved for dementia-related psychosis due to increased mortality risk in this population.
Medication interactions
Same interaction profile as oral Invega.